drugset / Trial / NCT00383370

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

NCT00383370

Phase 1 Completed 20 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the safety and tolerability of repeated intravitreal (ITV) administration of VEGF Trap.

Timeline

Start
2006-10
Primary completion
2007-09
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic Intravitreal